NCT06858410View on ClinicalTrials.gov

Lorlatinib Compared with Concurrent/ Sequential Chemoradiotherapy in Stage III ALK Positive Lung Adenocarcinoma

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

March 31, 2025

Primary Completion Date

March 31, 2030

Study Completion Date

August 31, 2030

Conditions
Neoadjuvant Non-Small Cell Lung Cancer
Interventions
DRUG

lorlatinib

Eligible patients will be registered to receive oral lorlatinib 100mg qd for 36 months during the treatment phase.

OTHER

concurrent/sequential platinum-based chemoradiotherapy

The choice of chemotherapy and will be determined by the investigator prior to treatment allocation and the radiotherapy also according to the clinical therapy regimen decided by the investigator.

All Listed Sponsors
lead

Guangdong Association of Clinical Trials

OTHER